Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Boussu – page 16

463 clinical trials in Boussu, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Boussu at a glance
463
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

463 trials in Boussu

Open in trial search

Colitis ulcerative+1

Not yet recruiting

Study of ABBV-701 and Risankizumab Combination vs Monotherapy in Adults with Moderately to Severely Active Crohn’s Disease or Ulcerative Colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Colitis ulcerative+1

Not yet recruiting

Study of risankizumab plus anti‑α4β7 integrin antibody versus each alone in adults with moderately to severely active Crohn’s disease or ulcerative colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Arthralgia

Not yet recruiting

Efficacy of embolization using ethyl esters of iodised fatty acids and ioversol in patients with painful joints (knee osteoarthritis, frozen shoulder, elbow tendinopathy)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ioversol
  • Sponsor:Assistance Publique Hopitaux De Paris

Autism spectrum disorder

Not yet recruiting

Effect of intranasal oxytocin versus placebo on stress and repetitive behaviors in adults with autism

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Oxytocin
  • Sponsor:UZ Leuven

Colorectal adenocarcinoma

Not yet recruiting

Phase 2 Study of ro7589831 with Pembrolizumab vs Pembrolizumab Alone in Adults with Advanced Colorectal Cancer (MSI‑High or dMMR)

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Vividion Therapeutics Inc.

Breast cancer+2

Not yet recruiting

Gedatolisib with drug combination versus standard therapy as first‑line treatment for patients with advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Celcuity Inc.

Adenocarcinoma gastric+1

Not yet recruiting

A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Anaemia+1

Not yet recruiting

Study of Elritercept (TAK‑226) with Ruxolitinib vs Placebo in Patients with Myelofibrosis and Anemia on Ruxolitinib Therapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Thrombosis prophylaxis

Not yet recruiting

Randomized trial of standard vs high-dose enoxaparin and sodium chloride for preventing clots in critically ill ICU patients at high risk of thrombosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Hopital Erasme

Chronic lymphocytic leukaemia+1

Not yet recruiting

Study of epcoritamab, venetoclax and ibrutinib in treatment‑naïve chronic lymphocytic leukemia patients with TP53 alterations

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:LYSARC

Non-small cell lung cancer+1

Not yet recruiting

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Crohn's disease

Not yet recruiting

Evaluation of Upadacitinib for Reducing Ileal Strictures in Patients with Crohn’s Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:UZ Leuven

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Boussu

What the registry says about research in the country

01 Hematologic Oncology

Innovative research focusing on multiple myeloma and diffuse large B-cell lymphoma, exploring new therapeutic combinations to improve treatment outcomes for patients with blood cancers.

  • Multiple Myeloma Treatment Studies
  • Lymphoma Therapy Research
  • Novel Drug Combinations

Current trials are evaluating advanced therapies for both newly diagnosed and relapsed/refractory cases.

02 Metabolic Health

Groundbreaking studies examining new approaches to managing obesity and weight management, with a focus on innovative therapeutic solutions combined with lifestyle modifications.

  • Weight Management Interventions
  • Long-term Weight Loss Studies
  • Lifestyle Integration Research

Research aims to evaluate new treatments alongside reduced-calorie diets and increased physical activity.

03 Nephrology

Advanced research in chronic kidney disease treatments, investigating novel approaches to reduce protein excretion and improve kidney function in affected patients.

  • Albumin Reduction Studies
  • Kidney Function Assessment
  • Standard of Care Enhancement

Trials are focused on developing new therapeutic options to complement existing treatment standards.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.